NCT04829604 2026-03-09ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Ambrx, Inc.Phase 2 Active not recruiting72 enrolled
NCT06014658 2026-03-02Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid TumorsMBrace TherapeuticsPhase 1/2 Recruiting130 enrolled